BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. HC Wainwright‘s price target would suggest a potential upside of 8.97% from the company’s current […]